Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgo Biloba + glucosamine sulfate is an investigational antifungal combination therapy developed by Ahmed A. H. Abdellatif at Al-Azhar University. The formulation combines the natural plant extract Ginkgo Biloba with glucosamine sulfate to treat superficial fungal infections such as tinea pedis (athlete's foot), tinea capitis, and tinea versicolor. It has been studied in various dosage forms, including oral hard gelatin capsules, topical hydrogels, and sprays. A Phase 1 clinical trial (NCT02882438) evaluated its efficacy and safety, comparing it against the standard antifungal fluconazole. The combination aims to provide a novel approach to treating chronic or treatment-resistant fungal infections using natural products with inherent antimicrobial properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ginkgo Biloba + glucosamine sulfate.